Abstract
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P
| Original language | English |
|---|---|
| Pages (from-to) | 1205-1214 |
| Number of pages | 10 |
| Journal | Journal of the American Society of Nephrology |
| Volume | 26 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Paricalcitol for secondary hyperparathyroidism in renal transplantation. / Trillini, Matias; Cortinovis, Monica; Ruggenenti, Piero; Loaeza, Jorge Reyes; Courville, Karen; Ferrer-Siles, Claudia; Prandini, Silvia; Gaspari, Flavio; Cannata, Antonio; Villa, Alessandro; Perna, Annalisa; Gotti, Eliana; Caruso, Maria Rosa; Martinetti, Davide; Remuzzi, Giuseppe; Perico, Norberto.
In: Journal of the American Society of Nephrology, Vol. 26, No. 5, 01.05.2015, p. 1205-1214.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Paricalcitol for secondary hyperparathyroidism in renal transplantation
AU - Trillini, Matias
AU - Cortinovis, Monica
AU - Ruggenenti, Piero
AU - Loaeza, Jorge Reyes
AU - Courville, Karen
AU - Ferrer-Siles, Claudia
AU - Prandini, Silvia
AU - Gaspari, Flavio
AU - Cannata, Antonio
AU - Villa, Alessandro
AU - Perna, Annalisa
AU - Gotti, Eliana
AU - Caruso, Maria Rosa
AU - Martinetti, Davide
AU - Remuzzi, Giuseppe
AU - Perico, Norberto
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P
AB - Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P
UR - http://www.scopus.com/inward/record.url?scp=84929377103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929377103&partnerID=8YFLogxK
U2 - 10.1681/ASN.2013111185
DO - 10.1681/ASN.2013111185
M3 - Article
C2 - 25194004
AN - SCOPUS:84929377103
VL - 26
SP - 1205
EP - 1214
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
SN - 1046-6673
IS - 5
ER -